Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1714
https://www.valueinhealthjournal.com/article/S1098-3015(18)32036-9/fulltext
Title :
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32036-9&doi=10.1016/j.jval.2018.04.1714
First page :
Section Title :
Open access? :
No
Section Order :
937